Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Hua Medicine

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Hua Medicine Announces Positive Results of the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)

              Contact the Supplier

              Lead Product(s): Dorzagliatin,Empagliflozin

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 26, 2020

              Details:

              The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.

              PharmaCompass__DigitalAd